Related Experiment Video

Updated: Jun 11, 2026

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

[Hydrophilic regulator hexapeptides as inhibitors of tumor cell multiple drug resistance]

V V Lebedev, S A Novikov, E Iu Rybalkina

    Antibiotiki I Khimioterapiia = Antibiotics and Chemoterapy [Sic]
    |June 30, 2010
    PubMed

    Insights

    New hydrophilic hexapeptides show promise in overcoming tumor cell multiple drug resistance (MDR) to chemotherapy. These peptides inhibit ATP-dependent transport proteins, potentially restoring cancer treatment effectiveness.

    Area of Science:

    • Oncology
    • Molecular Biology
    • Pharmacology

    Background:

    • Multiple drug resistance (MDR) in tumor cells significantly complicates chemotherapy efficacy.
    • MDR is often mediated by ATP-binding cassette (ABC) transport proteins that efflux drugs from cells.
    • Previous attempts to develop MDR-preventing agents have largely been unsuccessful.

    Purpose of the Study:

    • To investigate the potential of novel hydrophilic regulator hexapeptides as modulators of MDR.
    • To determine if these hexapeptides can restore tumor cell sensitivity to cytostatics.
    • To elucidate the mechanism by which hexapeptides affect MDR, specifically targeting the MRP protein.

    Main Methods:

    • Utilized three linear and cyclic hydrophilic hexapeptides as MDR modulators.
    • Assessed tumor cell sensitivity to cytostatics using the MTT assay and direct cell counting.
    • Investigated the effects of hexapeptides on human cancer cell lines: MCF7, KB8-5, and PC3.

    Main Results:

    • The tested hydrophilic hexapeptides enhanced tumor cell sensitivity to the cytostatic doxorubicin.
    • Hexapeptide-mediated inhibition of MDR was found to involve the ATP-dependent transport protein MRP.
    • Demonstrated effectiveness across multiple cancer cell lines, indicating broad applicability.

    Conclusions:

    • Hydrophilic linear and cyclic hexapeptides are effective modulators of tumor cell MDR.
    • These peptides show potential as novel therapeutic agents to overcome chemotherapy resistance.
    • Targeting MRP with these hexapeptides offers a promising strategy for enhancing cancer treatment outcomes.

    Related Concept Videos

    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against specific...
    Inhibition of Cdk Activity02:34

    Inhibition of Cdk Activity

    The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
    Drugs that Stabilize Microtubules01:15

    Drugs that Stabilize Microtubules

    Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
    Mitogens and the Cell Cycle02:38

    Mitogens and the Cell Cycle

    Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
    Combination Therapies and Personalized Medicine02:50

    Combination Therapies and Personalized Medicine

    Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
    The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...